Clinical trial
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
NCT05285891
Study timeline
Study start (actual)2023-02-07Date precision: day
Registry last updated2026-09-01
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Multiple Sclerosisverified · MONDO: multiple sclerosis
Interventions
OcrelizumabDRUG · verified · RxNorm: ocrelizumab
Sponsors & collaborators
Autoimmunity Centers of Excellencecollaborator
Rho Federal Systems Division, Inc.collaborator
Genentech, Inc.collaborator
Mapped research locations
New YorkNew York, United States1HoustonTexas, United States1BostonMassachusetts, United States1ChicagoIllinois, United States1PhiladelphiaPennsylvania, United States1DallasTexas, United States1Washington D.C.District of Columbia, United States1Oklahoma CityOklahoma, United States1RochesterNew York, United States1New HavenConnecticut, United States1RichmondVirginia, United States1WorcesterMassachusetts, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05285891 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.